创造消除肺癌治疗结果差异的机会：呼吁开展多样化研究人群的研究。对科汉等人的评论。非小细胞肺癌影像学与基因组学中的差异与多样性：对一个成熟的多中心数据库的评估。2023年，，2096。 （注：原文中部分逗号处信息缺失，译文按原样呈现）
Creating Opportunities to Eliminate Disparities in Lung Cancer Outcomes: A Call for Diverse Study Populations. Comment on Kohan et al. Disparity and Diversity in NSCLC Imaging and Genomics: Evaluation of a Mature, Multicenter Database. 2023, , 2096.
作者信息
Washington Caretia JeLayne, Braithwaite Dejana
机构信息
Department of Epidemiology, University of Florida, 2004 Mowry Rd., Gainesville, FL 32610, USA.
University of Florida Health Cancer Center, University of Florida, 2033 Mowry Rd., Gainesville, FL 32610, USA.
出版信息
Cancers (Basel). 2023 Jul 25;15(15):3762. doi: 10.3390/cancers15153762.
Abstract
We read with extensive interest the recently published paper, by Kohan et al., "Disparity and Diversity in NSCLC Imaging and Genomics: Evaluation of a Mature, Multicenter Database" [...].
摘要
我们怀着极大的兴趣阅读了科汉等人最近发表的论文《非小细胞肺癌影像学与基因组学的差异和多样性：对一个成熟的多中心数据库的评估》[...]。
相似文献
1
Creating Opportunities to Eliminate Disparities in Lung Cancer Outcomes: A Call for Diverse Study Populations. Comment on Kohan et al. Disparity and Diversity in NSCLC Imaging and Genomics: Evaluation of a Mature, Multicenter Database. 2023, , 2096.创造消除肺癌治疗结果差异的机会：呼吁开展多样化研究人群的研究。对科汉等人的评论。非小细胞肺癌影像学与基因组学中的差异与多样性：对一个成熟的多中心数据库的评估。2023年，，2096。 （注：原文中部分逗号处信息缺失，译文按原样呈现）
Cancers (Basel). 2023 Jul 25;15(15):3762. doi: 10.3390/cancers15153762.
2
Disparity and Diversity in NSCLC Imaging and Genomics: Evaluation of a Mature, Multicenter Database.非小细胞肺癌成像与基因组学中的差异和多样性：对一个成熟多中心数据库的评估
Cancers (Basel). 2023 Mar 31;15(7):2096. doi: 10.3390/cancers15072096.
3
The effectiveness of internet-based e-learning on clinician behavior and patient outcomes: a systematic review protocol.基于互联网的电子学习对临床医生行为和患者结局的有效性：一项系统评价方案。
JBI Database System Rev Implement Rep. 2015 Jan;13(1):52-64. doi: 10.11124/jbisrir-2015-1919.
4
Cancer among Immigrants: Diverse Histories, Diverse Disparities, Diverse Opportunities to Promote Equity.移民中的癌症：多样的历史、多样的差异、促进公平的多样机会。
Cancer Epidemiol Biomarkers Prev. 2022 Jul 1;31(7):1251-1253. doi: 10.1158/1055-9965.EPI-22-0337.
5
Comment on Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. 2021, , 1176.关于霍普金斯等人的评论。肺免疫预后指数在非小细胞肺癌患者一线阿替唑单抗联合治疗中的价值：IMPOWER150试验的亚组分析。2021年，，1176。
Cancers (Basel). 2021 Jul 20;13(14):3624. doi: 10.3390/cancers13143624.
6
Reply to Krupenko et al. Comment on "Lee et al. The Combination of Loss of ALDH1L1 Function and Phenformin Treatment Decreases Tumor Growth in KRAS-Driven Lung Cancer 2020, , 1382".对克鲁彭科等人的回复。关于“李等人。2020年，ALDH1L1功能丧失与二甲双胍治疗联合降低KRAS驱动的肺癌肿瘤生长，，1382”的评论。
Cancers (Basel). 2021 May 7;13(9):2238. doi: 10.3390/cancers13092238.
7
Cancer Genomics: Diversity and Disparity Across Ethnicity and Geography.癌症基因组学：种族和地理差异与多样性。
J Clin Oncol. 2016 Jan 1;34(1):91-101. doi: 10.1200/JCO.2015.62.0096. Epub 2015 Nov 17.
8
Racial and Ethnic Trends and Disparities in NSCLC.非小细胞肺癌的种族和民族趋势及差异
JTO Clin Res Rep. 2022 Jul 2;3(8):100374. doi: 10.1016/j.jtocrr.2022.100374. eCollection 2022 Aug.
9
Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.厄洛替尼和吉非替尼用于治疗先前化疗后进展的非小细胞肺癌（英国国家卫生与临床优化研究所技术评估162和175回顾）：一项系统评价与经济学评估
Health Technol Assess. 2015 Jun;19(47):1-134. doi: 10.3310/hta19470.
10
The Pursuit of Health Equity and Equality in Urologic Oncology: Where We Have Been and Where We Are Going.泌尿外科肿瘤学中对健康公平与平等的追求：我们的历程与未来方向
Eur Urol Focus. 2021 Sep;7(5):929-936. doi: 10.1016/j.euf.2021.09.002. Epub 2021 Sep 20.
本文引用的文献
1
Disparity and Diversity in NSCLC Imaging and Genomics: Evaluation of a Mature, Multicenter Database.非小细胞肺癌成像与基因组学中的差异和多样性：对一个成熟多中心数据库的评估
Cancers (Basel). 2023 Mar 31;15(7):2096. doi: 10.3390/cancers15072096.
2
Survival Differences by Comorbidity Burden among Patients with Stage I/II Non-Small-Cell Lung Cancer after Thoracoscopic Resection.I/II期非小细胞肺癌患者胸腔镜切除术后合并症负担与生存差异
Cancers (Basel). 2023 Mar 30;15(7):2075. doi: 10.3390/cancers15072075.
3
Rural-urban survival disparities for patients with surgically treated lung cancer.农村-城市肺癌手术治疗患者的生存差异。
J Surg Oncol. 2022 Dec;126(7):1341-1349. doi: 10.1002/jso.27045. Epub 2022 Sep 17.
4
Personalised Lung Cancer Screening (PLuS) study to assess the importance of coexisting chronic conditions to clinical practice and policy: protocol for a multicentre observational study.个体化肺癌筛查（PLuS）研究评估共存慢性疾病对临床实践和政策的重要性：一项多中心观察性研究方案。
BMJ Open. 2022 Jun 22;12(6):e064142. doi: 10.1136/bmjopen-2022-064142.
5
Cancer healthcare disparities among African Americans in the United States.美国非裔美国人的癌症医疗保健差距。
J Natl Med Assoc. 2022 Jun;114(3):236-250. doi: 10.1016/j.jnma.2022.01.004. Epub 2022 Mar 21.
6
Racial Disparities in Adherence to Annual Lung Cancer Screening and Recommended Follow-Up Care: A Multicenter Cohort Study.种族差异对年度肺癌筛查和推荐的随访护理的遵从性的影响：一项多中心队列研究。
Ann Am Thorac Soc. 2022 Sep;19(9):1561-1569. doi: 10.1513/AnnalsATS.202111-1253OC.
7
Accounting for EGFR Mutations in Epidemiologic Analyses of Non-Small Cell Lung Cancers: Examples Based on the International Lung Cancer Consortium Data.在非小细胞肺癌的流行病学分析中考虑 EGFR 突变：基于国际肺癌研究协会数据的实例。
Cancer Epidemiol Biomarkers Prev. 2022 Mar 1;31(3):679-687. doi: 10.1158/1055-9965.EPI-21-0747.
8
Race and Genetic Ancestry in Medicine - A Time for Reckoning with Racism.医学中的种族与遗传血统——正视种族主义的时刻
N Engl J Med. 2021 Feb 4;384(5):474-480. doi: 10.1056/NEJMms2029562. Epub 2021 Jan 6.
9
Surveillance Practice Patterns after Curative Intent Therapy for Stage I Non-Small-Cell Lung Cancer in the Medicare Population.医疗保险人群中 I 期非小细胞肺癌根治性治疗后的监测实践模式
Lung Cancer. 2016 Sep;99:200-7. doi: 10.1016/j.lungcan.2016.07.017. Epub 2016 Jul 19.
10
The genetic ancestry of African Americans, Latinos, and European Americans across the United States.美国非裔美国人、拉丁裔和欧洲裔美国人的遗传祖先。
Am J Hum Genet. 2015 Jan 8;96(1):37-53. doi: 10.1016/j.ajhg.2014.11.010. Epub 2014 Dec 18.
Zotero 插件